EVOQ Partners With Gilead On NanoDisc Approach To RA, Lupus

Michigan biotech follows 2021 collaboration in autoimmune disease with Amgen with its second tie-up, teaming up with Gilead in rheumatoid arthritis and systemic lupus erythematosus.

Nanotech
EVOQ's approach involves delivering antigens therapeutically via nanotechnology • Source: Shutterstock

Privately held EVOQ Therapeutics is using a new collaboration in autoimmune disease with Gilead Sciences, Inc., along with a similar partnership inked with Amgen, Inc., to get its NanoDisc delivery technology off the ground. During a 3 January interview to discuss the Gilead tie-up, CEO William Brinkerhoff said EVOQ saw substantial early potential for its platform in cancer but will now be looking at rheumatoid arthritis and systemic lupus erythematosus.

Launched in 2016 with intellectual property in-licensed from nearby University of Michigan, EVOQ uses a platform technology that takes...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

Vor Is Reborn With New CEO And Ambitious RemeGen Autoimmune Pact

 
• By 

The biotech had been looking at options to survive since May.

Kymera Inks CDK2 Deal With Gilead

 

Deal Snapshot: The biotech will receive up to $750m from Gilead for molecular glue degraders against CDK2.

Sanofi Links Up Again With Formation To Take Gusacitinib Down New Path

 
• By 

Deal Snapshot: The Paris-headquartered company has licensed gusacitinib, which was in development for chronic hand eczema, but Sanofi will pursue a new indication for the dual JAK/SYK inhibitor.

Stock Watch: When The Biotech Bandwagon Music Stops

 
• By 

The number of viable biotech companies exploiting a particular technology should be limited by intellectual property but the number of biotech IPOs exploiting that same technology always seems greater than those with freedom to operate.

More from Business

Biogen’s Spinraza Follow-On May Offer Disease-Modifying Potential

 
• By 

Biogen hopes to move directly from Phase I to Phase III with salanersen, a higher-potency therapy that uses the same mechanism of action as Spinraza.

Kymera Inks CDK2 Deal With Gilead

 

Deal Snapshot: The biotech will receive up to $750m from Gilead for molecular glue degraders against CDK2.

Nektar Bounces Back As Eczema Drug Rezpeg Heads For Phase III

 
• By 

Lilly-rejected candidate impresses in Phase IIb atopic dermatitis trial.